Assess whether a CMC change is a comparability or a new product (eb577f)

Situation

A CMO 483 that maps to the NDA CMC module put CMC comparability package for a site change in front of regulatory-affairs lead in a rare-disease team designing a pediatric plan. This Pharma & Life Sciences / Pharmacovigilance close is a CMC change is from CMC comparability package for a site change, and the live options are A CMC change is a comparability, A new product.

Decision

Regulatory-affairs lead in a rare-disease team designing a pediatric plan must choose A CMC change is a comparability / A new product using CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• The population in CMC comparability package for a site change is the one a CMO 483 that maps to the NDA CMC module named, so A CMC change is a comparability follows for this Pharmacovigilance file.
• The population in CMC comparability package for a site change is adjacent only to a CMO 483 that maps to the NDA CMC module; A new product is the honest Pharma & Life Sciences call.
• A rare-disease team designing a pediatric plan already contained a CMO 483 that maps to the NDA CMC module before CMC comparability package for a site change arrived; no new Pharmacovigilance path.
• Provenance on CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module is broken; do not pick A CMC change is a comparability or A new product yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether CMC comparability package for a site change supports the labeled claim regulatory-affairs lead would keep.
• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a CMO 483 that maps to the NDA CMC module and write the one fact that would move a CMC change is for regulatory-affairs lead.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.